Ono Pharmaceutical (OTCMKTS:OPHLF) Issues Quarterly Earnings Results

Ono Pharmaceutical (OTCMKTS:OPHLF) posted its earnings results on Friday. The company reported $0.40 earnings per share for the quarter, topping analysts’ consensus estimates of $0.25 by $0.15, Zacks reports. Ono Pharmaceutical had a return on equity of 8.55% and a net margin of 13.51%.

Ono Pharmaceutical Stock Performance

Ono Pharmaceutical stock remained flat at $14.61 during trading hours on Friday. The company’s fifty day simple moving average is $14.33 and its two-hundred day simple moving average is $14.77. Ono Pharmaceutical has a 12-month low of $10.27 and a 12-month high of $18.67. The company has a debt-to-equity ratio of 0.10, a quick ratio of 2.56 and a current ratio of 3.02. The company has a market cap of $6.87 billion, a PE ratio of 14.76 and a beta of 0.34.

Analysts Set New Price Targets

Separately, Zacks Research raised shares of Ono Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research report on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, According to data from MarketBeat.com, Ono Pharmaceutical has an average rating of “Strong Buy”.

Ono Pharmaceutical Company Profile

Ono Pharmaceutical Co, Ltd., founded in 1717 and headquartered in Osaka, Japan, is a research‐based pharmaceutical company specializing in the discovery, development and marketing of innovative therapies. With origins as a traditional pharmacy, Ono has grown into a global biopharmaceutical entity focused on delivering new treatment options across several therapeutic areas, including oncology, immunology, cardiovascular and antiviral diseases. The company conducts comprehensive research programs spanning early drug discovery through to clinical development.

One of Ono’s most recognized products is the immune checkpoint inhibitor nivolumab, marketed in collaboration with Bristol-Myers Squibb under the trade name Opdivo.